These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11815891)

  • 1. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion.
    Brown GC; Brown MM; Sharma S; Busbee B; Brown H
    Ophthalmic Epidemiol; 2002 Feb; 9(1):1-10. PubMed ID: 11815891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO).
    Taylor M; Serbetci E; Ferreira A; Gairy K; Lewis L; Blouin J; Mitchell P
    J Med Econ; 2014 Jun; 17(6):423-34. PubMed ID: 24673384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic considerations of macular edema therapies.
    Smiddy WE
    Ophthalmology; 2011 Sep; 118(9):1827-33. PubMed ID: 21507488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-utility analysis of interventions for severe proliferative vitreoretinopathy.
    Brown GC; Brown MM; Sharma S; Busbee B; Landy J
    Am J Ophthalmol; 2002 Mar; 133(3):365-72. PubMed ID: 11860974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
    Adedokun L; Burke C
    Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization.
    Brown GC; Brown MM; Sharma S; Brown H; Tasman W
    Ophthalmology; 2000 Jul; 107(7):1374-80. PubMed ID: 10889115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Retina; 2003 Jun; 23(3):279-87; ; quiz 443-4. PubMed ID: 12824826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
    Haig J; Barbeau M; Ferreira A
    J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis.
    Brown GC; Brown MM; Sharma S; Busbee B; Brown H
    Retina; 2000; 20(4):331-7. PubMed ID: 10950408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Curr Opin Ophthalmol; 2000 Jun; 11(3):175-9. PubMed ID: 10977223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC; Brown MM; Turpcu A; Rajput Y
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser.
    Parodi MB; Spasse S; Iacono P; Di Stefano G; Canziani T; Ravalico G
    Ophthalmology; 2006 Dec; 113(12):2237-42. PubMed ID: 16996596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.
    Buyru Özkurt Y; Akkaya S; Aksoy S; Şimşek MH
    Eur J Ophthalmol; 2018 Nov; 28(6):690-696. PubMed ID: 29696993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of treatment for threshold retinopathy of prematurity.
    Brown GC; Brown MM; Sharma S; Tasman W; Brown HC
    Pediatrics; 1999 Oct; 104(4):e47. PubMed ID: 10506272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment.
    Parodi MB; Iacono P; Bandello F
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1647-51. PubMed ID: 25382074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grid laser treatment of macular edema in macular branch retinal vein occlusion.
    Battaglia Parodi M; Saviano S; Bergamini L; Ravalico G
    Doc Ophthalmol; 1999; 97(3-4):427-31. PubMed ID: 10896360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical applications of cost analysis of diabetic macular edema treatments.
    Smiddy WE
    Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.